Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author COSTA, Leandro Menezes Alves da FMUSP-HC
HUEB, Whady FMUSP-HC
NOMURA, Cesar Higa FMUSP-HC
HUEB, Alexandre Ciappina FMUSP-HC
VILLA, Alexandre Volney FMUSP-HC
OIKAWA, Fernando Teiichi Costa FMUSP-HC
MELO, Rodrigo Morel Vieira de FMUSP-HC
REZENDE, Paulo Cury FMUSP-HC
SEGRE, Carlos Alexandre Wainrober FMUSP-HC
GARZILLO, Cibele Larrosa FMUSP-HC
LIMA, Eduardo Gomes FMUSP-HC
RAMIRES, Jose Antonio Franchini FMUSP-HC
KALIL FILHO, Roberto FMUSP-HC
dc.date.issued 2017
dc.identifier.citation MEDICINE, v.96, n.6, article ID e6053, 7p, 2017
dc.identifier.issn 0025-7974
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/20001
dc.description.abstract The release of myocardial necrosis biomarkers after off-pump coronary artery bypass grafting (OPCAB) frequently occurs. However, the correlation between biomarker release and the diagnosis of procedure-related myocardial infarction (MI) (type 5) has been controversial. This study aimed to evaluate the amount and pattern of cardiac biomarker release after elective OPCAB in patients without evidence of a new MI on cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE). Patients with normal baseline cardiac biomarkers referred for elective OPCAB were prospectively included. CMR with LGE was performed in all patients before and after interventions. Measurements of troponin I (cTnI) and creatine kinase MB fraction (CK-MB) were systematically performed before and after the procedure. Patients with new LGE on the postprocedure CMR were excluded. All of the 53 patients without CMR evidence of a procedure-related MI after OPCAB exhibited a cTnI elevation peak above the 99th percentile. In 48 (91%), the peak value was > 10 times this threshold. However, 41 (77%) had a CK-MB peak above the limit of the 99th percentile, and this peak was > 10 times the 99th percentile in only 7 patients (13%). The median peak release of cTnI was 0.290 (0.8-3.7) ng/mL, which is 50-fold higher than the 99th percentile. In contrast with CK-MB, considerable cTnI release often occurs after an elective OPCAB procedure, despite the absence of new LGE on CMR.
dc.language.iso eng
dc.publisher LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof Medicine
dc.rights openAccess
dc.subject biomarkers; coronary artery bypass grafting; coronary artery disease; myocardial infarction; troponin
dc.subject.other mass-v trial; troponin-t; universal definition; randomized-trial; surgery; revascularization; intervention; angioplasty; mortality; diagnosis
dc.title Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance
dc.type article
dc.rights.holder Copyright LIPPINCOTT WILLIAMS & WILKINS
dc.description.group LIM/11
dc.identifier.doi 10.1097/MD.0000000000006053
dc.identifier.pmid 28178154
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author COSTA, Leandro Menezes Alves da:FM:
hcfmusp.author HUEB, Whady:FM:MCP
hcfmusp.author NOMURA, Cesar Higa:HC:INCOR
hcfmusp.author HUEB, Alexandre Ciappina:HC:INCOR
hcfmusp.author VILLA, Alexandre Volney:HC:INCOR
hcfmusp.author OIKAWA, Fernando Teiichi Costa:HC:INCOR
hcfmusp.author MELO, Rodrigo Morel Vieira de:HC:INCOR
hcfmusp.author REZENDE, Paulo Cury:HC:INCOR
hcfmusp.author SEGRE, Carlos Alexandre Wainrober:HC:INCOR
hcfmusp.author GARZILLO, Cibele Larrosa:HC:INCOR
hcfmusp.author LIMA, Eduardo Gomes:HC:INCOR
hcfmusp.author RAMIRES, Jose Antonio Franchini:FM:MCP
hcfmusp.author KALIL FILHO, Roberto:FM:MCP
hcfmusp.origem.id WOS:000394391200035
hcfmusp.origem.id 2-s2.0-85014126558
hcfmusp.publisher.city PHILADELPHIA
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Borst C, 1996, J AM COLL CARDIOL, V27, P1356, DOI 10.1016/0735-1097(96)00039-3
· Croal BL, 2006, CIRCULATION, V114, P1468, DOI 10.1161/CIRCULATIONAHA.105.602370
· Domanski MJ, 2011, JAMA-J AM MED ASSOC, V305, P585, DOI 10.1001/jama.2011.99
· Grobben RB, 2014, CLIN LAB MED, V34, P99, DOI 10.1016/j.cll.2013.11.013
· Hueb W, 2016, ANN THORAC SURG, V101, P2202, DOI 10.1016/j.athoracsur.2015.11.034
· Hueb W, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-65
· Januzzi JL, 2002, J AM COLL CARDIOL, V39, P1518, DOI 10.1016/S0735-1097(02)01789-8
· Kathiresan S, 2004, AM J CARDIOL, V94, P879, DOI 10.1016/j.amjcard.2004.06.022
· Kim RJ, 2008, CIRCULATION, V117, P629, DOI 10.1161/CIRCULATIONAHA.107.723262
· Klatte K, 2001, J AM COLL CARDIOL, V38, P1070, DOI 10.1016/S0735-1097(01)01481-4
· Lim CCS, 2011, J AM COLL CARDIOL, V57, P653, DOI 10.1016/j.jacc.2010.07.058
· Mohammed AA, 2009, CIRCULATION, V120, P843, DOI 10.1161/CIRCULATIONAHA.108.837278
· Moussa ID, 2013, J AM COLL CARDIOL, V62, P1563, DOI 10.1016/j.jacc.2013.08.720
· Pegg TJ, 2011, HEART, V97, P810, DOI 10.1136/hrt.2010.213462
· Thygesen K, 2012, EUR HEART J, V33, P2551, DOI 10.1093/eurheartj/ehs184
· van Gaal WJ, 2011, EUROINTERVENTION, V6, P703, DOI 10.4244/EIJV6I6A119
· Wu E, 2001, LANCET, V357, P21, DOI 10.1016/S0140-6736(00)03567-4
dc.description.index MEDLINE
dc.identifier.eissn 1536-5964
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 1


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics